NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP China Pharmas » Simcere Pharmaceutical Group  1  2  » 
found files: 23
Simcere Pharmaceutical Group »19/04/2007 [Finance]
Simcere Pharmaceutical Group Announces Pricing of Initial Public Offering on NYSE

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market, announced today that its initial public offering of 15,625,000 American Depositary Shares (ADSs), each representing two ordinary shares, was priced at an initial public offering price of $14.50 per ADS. The ADSs will begin trading on the New York Stock Exchange on April 20, 2007 under the symbol ''SCR.''...   more»


Simcere Pharmaceutical Group »03/06/2007 [Industry news]
Simcere Pharmaceutical Group is looking to build its future on research

Flush with cash from its US IPO, Simcere Pharmaceutical Group is looking to build its future on research. Late last month, Simcere weighed in with the largest IPO on the New York Stock Exchange for an Asian pharmaceutical company, raising 261 mln usd. Now it plans to put some of that money to work. 'We need to consider both the long-term and the short-term,' said Jinsheng Ren, chairman and CEO. 'Pharmaceutical technology can really set companies apart in China and that is why we say R & D is our focus.' "THIS HIGHLY RESPECTED COMPANY COULD BE A GOOD PARTNER FOR HLS"...   more»


Simcere Pharmaceutical Group »04/10/2007
Simcere Pharmaceutical Group, a manufacturer of anti-cancer medication Endu, said it agreed to buy a 51% stake in Boda Pharmaceutical Co., Ltd

This company is off on the acquisition trail !...   more»


Simcere Pharmaceutical Group »26/11/2007 [Company watch]
Simcere Acquires Nanjing Tung Chit

Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, announced today that it has acquired 100% of Master Luck Corporation Limited, which holds 85.7% of Nanjing Tung Chit Pharmaceutical Co., Ltd. ("Tung Chit"), for a total cash consideration of RMB32.6 million (US$4.4 million). Tung Chit is a fast-growing manufacturer and supplier of anti-cancer drugs in China. Its leading product is a nedaplatin injection, trademarked as Jiebaisu, a first-to-market platinum based chemotherapeutic drug approved for the treatment of a wide range of solid tumors, including head-and-neck cancer, small cell and non-small cell lung cancer and esophageal cancer. Since its launch, Jiebaisu has been used by a number of major Chinese hospitals, specializing in cancer treatment, in many provinces across China. According to the China Hospital Drug Information, Jiebaisu's share of the nedaplatin market in China was over 80 percent in 2006. Being a new generation, broad spectrum platinum based chemotherapeutic drug, nedaplatin is expected to have significant growth potential in China....   more»


Simcere Pharmaceutical Group »20/03/2008 [Company watch]
Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Sales appointments

Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announces the appointment of Mr. Mark Chen, Pei-Chi as Vice President of Marketing and the promotion of Baoxing Zha and Dasheng Sun as the Vice Presidents of Hospital Sales and Retail Sales respectively....   more»


Simcere Pharmaceutical Group »22/04/2008 [Company watch]
Simcere acquires 70% in Wuhu Zhong Ren Pharma

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, has signed a definitive agreement to acquire a 70% equity interest in Wuhu Zhong Ren Pharmaceutical for a total cash consideration of RMB 64.82 million ($9.26 million). This transaction is consistent with Simcere's strategy to focus on first-to-market and innovative new drugs and expand its anti-cancer product portfolio. Zhong Ren Pharmaceutical is a Chinese drug manufacturer specializing in the production of sustained release anti-tumor implants. Its key product SinoFuan (fluorouracil implant), is proven to effectively inhibit the growth of tumors, and is the only sustained release anti-tumor implant approved by the State Food and Drug Administration (SFDA). SinoFuan is commonly used to treat cancers of the digestive tract and is a favored choice for use during surgery. No similar product exists on the Chinese market today. The distribution of SinoFuan through Simcere's established marketing channels will enhance Simcere's offerings in the anti-cancer drug market, benefit cancer patients across China and create greater value for Simcere shareholders....   more»


Simcere Pharmaceutical Group »18/05/2008 [Company watch]
Simcere Pharmaceutical Group Announces SFDA Approval Of First-To-Market Generic Biapenem Injection A

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, recently announced that it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market a first-to-market generic Biapenem injection under the brand name Anxin. Anxin is the first Biapenem injection approved for sale in China, and will be used for the treatment of serious infections. Biapenem is a member of the fast-growing carbenicillin family, like Tienam from Merck & Co. Inc. and Mepem from Sumitomo Pharmaceuticals Co. Ltd., with a potential market in China of RMB1.6 billion. This family of drug has seen an approximate 30% year over year growth rate in China over the last three years. As is the case with first-to- market branded generics in China, Anxin will enjoy an exclusive four-year market monitoring period, during which the SFDA will not accept further requests for approval of pharmaceuticals with the same chemical structure, dosage form and indication, that have not yet entered into clinical trial. Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere, commented, "The approval of Anxin, a Simcere developed Biapenem injection, strengthens the company's antibiotic product portfolio in line with our strategy to focus on first-to-market generic and innovative drugs. More importantly, it provides a new and effective treatment for patients with serious infections who have experienced resistance to other antibiotics."...   more»


Simcere Pharmaceutical Group »06/08/2008 [Company watch]
Simcere’s Q2 Fails Expectations

Simcere Pharmaceutical Group (SCR) reported significantly improved Q2 financials Tuesday, but the results came in below analysts' estimates and the company reduced its guidance for full-year 2008. The disappointments caused a 4% selloff in the company’s stock price. Simcere makes branded generic pharmaceuticals for the China market as well as the patented cancer therapeutic Endu, a biologic drug. Simcere said it faced two problems in Q2: Endu revenue growth was lower than expected because the company restructured its Endu sales force. Also, Simcere is giving away Endu to accelerate participation in a Phase IV clinical trial of the drug, resulting in lower-than-projected sales. On first blush, Simcere’s Q2 report showed a steady, though not spectacular year-over-year improvement. Revenues climbed a solid 30% to 436 million RMB ($63.6 million) and net income was up a less-impressive 14.5%, at 95 million RMB ($13.9 million). Gross margins dropped a couple of percentage points to 81.7% and net margin was off by 3% at a still healthy 22%. The net income works out to a profit of 1.52 RMB ($0.22) per share. These are decent results, though the decline in profitability is a setback. However, analysts had called for 458 million RMB of revenue, which Simcere missed by 22 million RMB or $3.2 million. Simcere’s Q2 net income was actually just a little higher than estimates, despite the revenue shortfall. Because Q2 was a disappointment, Simcere trimmed its full-year projected revenues by 300 million RMB to a 1.7 billion-1.8 billion range. The company still expects its net income to hit somewhere between 390 million RMB and 400 million RMB or $58 million. That yields a price-to-earnings ratio for 2008 of just under 13, a bargain for a company that is growing at around 20% annually and has an enviable profit margin. Simcere recorded 10.1 million RMB in Q2 revenue from its first-to-market products, Jiebaishu and Sinofuan, both of them cancer drugs. These products were not available in Q2 of 2007. In a conference call with investors, following release of its Q2 report, Simcere’s management said the company plans to increase its marketing activities to drive revenues higher and to continue seeking M&A opportunities. In mid-session trading, Simcere was down 44 cents at $12.10 in moderately heavy trading....   more»


Simcere Pharmaceutical Group »04/09/2008 [Company watch]
Simcere Shows Positive Data from Cancer Drug Trial

Simcere Pharma (SCR) reported that interim results from a Phase IV trial of its patented anti-cancer drug Endu showed the drug displayed both safety and efficacy. The data were in line with Endu’s Phase III trial. An anti-angiogenesis drug, Endu is a modified version of recombinant human endostatin. It is approved for use in China against non-small cell lung cancer, administered as an adjunct to platinum-class chemotherapy. Simcere said the results showed that Endu has a synergistic effect in this patient population, though the trial did not include patients who received platinum-class chemotherapy by itself. After 648 patients, Endu produced overall response rates of 24% and therapeutic activity in 81% of patients. In newly-treated patients, the response rate was 31%, a level that dropped to 17% in previously treated patients. Similar to the response rate, the drug was tolerated by patients at about the same levels as was evident in the Phase III trial. The trial has a single arm, open label design. In the trial, Endu has been administered to more than 2000 patients with advanced-stage NSCLC. Full results from the Phase IV test are expected in 2010. When the company announced its Q2 results, Simcere said the fall-off in Endu revenue during the period was due to the Phase IV trial. Patients meeting the trial’s criteria receive the drug for free. Endu is approved as a first-line treatment for NSCLC in China....   more»


Simcere Pharmaceutical Group »16/09/2008 [Company watch]
Simcere Pharmaceutical promotes senior executives

Simcere Pharmaceuticals announced the promotions of Mr. Jindong Zhou and Mr. Xiaojin Yin to Executive Vice President and Senior Vice President, respectively, and the appointment of Mr. Qingsen Li to the newly created position of Vice President of Human Resources....   more»


Simcere Pharmaceutical Group »13/01/2009
Simcere Issues Net Income Warning for 2008

Simcere Pharmaceutical Group (NYSE: SCR) announced that, according to preliminary figures, the company’s full-year 2008 revenue was 1.72 billion RMB ($252 million). That is up 24% over 2007, but at the low end of its previously announced 1.7 billion to 1.8 billion RMB estimated range. A more negative note is that net income will be about 10% below the forecast, which was 390 million RMB to 400 million RMB. This indicates earnings of about 355 million RMB ($52 million), only an 18% improvement over 2007....   more»


Simcere Pharmaceutical Group »15/03/2009 [Company watch]
Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today reported unaudited financial results for the quarter and fiscal year ended December 31, 2008....   more»


Simcere Pharmaceutical Group »07/05/2009 [Company watch]
Simcere seeks to manufacture Zanamivir

Simcere Pharmaceutical, a manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, has announced that the company is seeking approval to manufacture and sell products containing Zanamivir....   more»


Simcere Pharmaceutical Group »21/08/2009 [Industry news]
Forty-two of Simcere Pharmaceutical Group Generic Drugs Enter the China Essential Drug List

Simcere Pharmaceutical Group a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced that forty-two of its generic drugs have been included in China\'s Essential Drug List, which was issued by China Ministry of Health on August 18, 2009....   more»


Simcere Pharmaceutical Group »25/09/2009 [Company watch]
Simcere Teams Up with Cancer Centre to Develop Drugs

Simcere Pharmaceutical Group and Sun Yat-Sen University Cancer Center of Guangzhou have established a strategic relationship to develop cancer drugs....   more»


Simcere Pharmaceutical Group »20/10/2009 [Company watch]
Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals

Simcere Pharmaceutical Group a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China....   more»


Simcere Pharmaceutical Group »28/10/2009 [Company watch]
Simcere Gains Majority Control of Vaccine Subsidiary

Simcere Pharmaceutical Group (NYSE: SCR), a China company that makes branded generic and proprietary pharmaceuticals, now controls a majority 50.77% of its vaccine subsidiary, Jiangsu Yanshen Biological Technology Stock Co., Ltd. Simcere bought its original 37.5% stake in Jiangsu Yanshen in May 2009....   more»


Simcere Pharmaceutical Group »09/11/2009 [Company watch]
Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd....   more»


Simcere Pharmaceutical Group »03/12/2009 [Company watch]
Simcere Shuts Down Production in Rabies Vaccine Subsidiary over Quality Control

Simcere Pharmaceutical Group (NYSE: SCR) has stopped a production line at its recently acquired vaccine subsidiary while it reviews quality control systems in the company. Simcere bought a 37.5% stake in Jiangsu Yanshen Biological Technology Stock Co. in May, and then upped its ownership to just over 50% on October 24, 2009. It closed the production line on November 30....   more»


Simcere Pharmaceutical Group »11/02/2010 [Company watch]
Simcere Pharmaceutical Group Receives FDA Approval to Manufacture and Sell Zanamivir in China

Simcere Pharmaceutical Group , a leading pharmaceutical company specialising in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.